Patents Examined by Lakia J Jackson-Tongue
  • Patent number: 10300120
    Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: May 28, 2019
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Ashraf S. Ibrahim, Bradley J. Spellberg, Yue Fu, Scott G. Filler, Michael R. Yeaman
  • Patent number: 10300138
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: May 28, 2019
    Assignee: SNIPR Technologies Limited
    Inventor: Jasper Clube
  • Patent number: 10300139
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: May 28, 2019
    Assignee: SNIPR TECHNOLOGIES LIMITED
    Inventor: Jasper Clube
  • Patent number: 10293004
    Abstract: A butyrate-producing bacterium belonging to Anaerostipes hadrus is provided. The amount of butyrate produced is at least 1.5 times that of Anaerostipes hadrus YIT 10092T (DSM 3319T) and is measured by thawing a frozen stock solution of the bacterial strain (a 10% (w/v) skim milk-2% sodium glutamate solution with suspended bacterial cells) (cell count: 2.0 to 5.5×1010 cells/mL), inoculating the solution at 1% to 4 mL of a PY liquid medium supplemented with 33 mM sodium acetate and 0.5 (w/v) % glucose (PYGA medium), followed by anaerobic culture at 37° C. for 24 hours, then inoculating the culture solution at 1% to a PYGA medium, followed by anaerobic culture at 37° C. for 24 hours, then inoculating the culture solution at 1% to a PY medium containing 33 mM sodium acetate and 0.5 (w/v) % L-sorbose, followed by anaerobic culture at 37° C. for 24 hours, and then measuring the butyrate concentration.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: May 21, 2019
    Assignee: KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Tadashi Sato, Shiro Kusuhara, Wakae Yokoi, Masahiko Ito, Kouji Miyazaki, Akira Kushiro
  • Patent number: 10278984
    Abstract: Methods and Compositions involving the administration of guanosine, identified as Toll like receptor (TLR) 2 and 4 agonists, that will be useful for enhancing the potency of vaccine and cancer immunotherapies are disclosed. Method of preventing and treating cancer and infection by administration of guanosine or pro-drugs of guanosine, or a precursor of guanosine are also disclosed. Compositions of guanosine or a pro-drug of guanosine or precursor of guanosine may be formulated as pharmaceutical dosage forms and components can be assembled as kits. Methods for activating TLRs with guanosine to enhance an immune response and to potentiate/augment antiviral, antibacterial or anticancer effects of other antiviral, anti-bacterial and anticancer therapeutic agents are also disclosed.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 7, 2019
    Assignee: Nitor Therapeutics
    Inventor: Shanta Bantia
  • Patent number: 10279023
    Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 7, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida
  • Patent number: 10274491
    Abstract: The present invention relates to methods for the diagnosing, prognosing, monitoring, differentiating, treating, and managing of Lyme disease in a subject. The methods according to the invention are characterized by the detection of a biomarker signature comprised of a combination of two or more analytes indicative of disease.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: April 30, 2019
    Assignee: VERAMARX, INC.
    Inventors: Whitney Richards, Floyd E. Taub, Robert A. Rubin
  • Patent number: 10264795
    Abstract: Streptomyces badius SP6C4 strain has an antimicrobial activity against an insect pathogen or a strawberry fungal disease pathogen isolated from strawberry pollen. The growth of an insect pathogen and a strawberry fungal disease pathogen is suppressed by Streptomyces badius SP6C4 strain isolated from strawberry pollen. Streptomyces badius SP6C4 strain can be used as an environmentally friendly biological agrochemical which is free of any environmental contamination yielded as a side effect of an agrochemical or any human toxicity caused by residual agrochemicals, and, by having an excellent effect of controlling American foul brood, chalk brood, and strawberry flower mold disease, it can be very advantageously used in terms of an industrial use.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: April 23, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Youn-Sig Kwak, Da-Ran Kim
  • Patent number: 10265392
    Abstract: The present invention pertains to a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier for use in a method to reduce in a pig the shedding of Lawsonia intracellularis bacteria associated with subclinical infection with Lawsonia intracellularis, by systemic administration of the vaccine to the pig.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: April 23, 2019
    Assignee: Intervet Inc.
    Inventor: Antonius Arnoldus Christiaan Jacobs
  • Patent number: 10254296
    Abstract: The instant invention relates to a qualitative predictive method, to a method, use and kit applied to the early differential diagnosis of the most prevalent forms of bacterial and viral meningitis, enabling to detect and distinguish the different forms of meningitis. The invention uses a qualitative predictive method based on combined detection and sequential analysis of the presence/absence of at least three out of four specific biomarkers.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: April 9, 2019
    Assignee: FUNDAÇÃO OSWALDO CRUZ
    Inventors: Roney Santos Coimbra, Rosiane A da Silva Pereira, Guilherme Correa De Oliveira, Ana Paula Cordeiro
  • Patent number: 10246514
    Abstract: Described herein is the development of recombinant single domain antibodies, also known as nanobodies, that may provide better therapeutic results or be useful for diagnostic applications of B-cell lymphomas, or in other applications where an antibody to CD20 may be useful.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: April 2, 2019
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Jinny Lin Liu, Daniel Zabetakis, Ellen R. Goldman, George P. Anderson
  • Patent number: 10245305
    Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: April 2, 2019
    Assignee: Allergan, Inc.
    Inventor: Eric R. First
  • Patent number: 10246677
    Abstract: One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: April 2, 2019
    Inventor: Bobban Subhadra
  • Patent number: 10233234
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: March 19, 2019
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
  • Patent number: 10226523
    Abstract: Embodiments of the present disclosure include vaccine compositions comprising a TcdB toxin or toxoid derived therefrom. The TcdB toxin may be derived from a hypervirulent strain of C. difficile. A further embodiment is directed to a method of conferring an active immunity against a C. difficile infection in a subject by administering the vaccine composition to the subject.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: March 12, 2019
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Jordi M. Lanis, Jimmy D. Ballard
  • Patent number: 10214592
    Abstract: The purpose of the present invention is to provide a monoclonal antibody that is useful in specifically assaying tartrate resistant acid phosphatase 5b (TRACP-5b). A hybridoma producing a monoclonal antibody against TRACP-5b, said monoclonal antibody showing higher reactivity with TRACP-5b than with tartrate resistant acid phosphatase 5a (TRACP-5a) and, therefore, being specific to TRACP-5b, is obtained by cell fusion using, as an antigen, human recombinant TRACP-5b purified from silkworm silk gland. By using this monoclonal antibody, TRACP-5b in a specimen can be highly sensitively and specifically detected.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: February 26, 2019
    Assignee: NITTO BOSEKI CO., LTD.
    Inventors: Wataru Kikuchi, Kumiko Sasagawa, Kenta Noda
  • Patent number: 10214569
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: February 26, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • Patent number: 10201599
    Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: February 12, 2019
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Jeremy Kroll, Mike Roof
  • Patent number: 10201594
    Abstract: Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: February 12, 2019
    Assignee: Revance Therapeutics, Inc.
    Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
  • Patent number: 10195273
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: February 5, 2019
    Assignee: SNIPR TECHNOLOGIES LIMITED
    Inventor: Jasper Clube